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This paper performs an overview of the essential components in crisis management and 
an empirical analysis of the crisis management preparedness of the pharmaceutical com-
panies in Greece. It also presents a best practice model for the business leaders in the Greek 
pharmaceutical market to help them to assess their level of preparedness and create their 
own crisis management plans, through adapting the current study fi ndings. The results, 
obtained from an original questionnaire survey, confi rm that the pharmaceutical industry 
is especially vulnerable to crisis situations and that the Greek economic crisis had a severe 
adverse impact on that industry. Nonetheless, the survey fi ndings suggest that the phar-
maceutical companies in Greece have a respectable level of crisis management adoption, 
although there is still room for improvements to address various types of future market 
risks.
Keywords: crisis preparedness, risk management adoption, pharmaceutical sector, 
Greece.
1. Introduction
Crises are regarded to be inevitable and they can be hardly predicted or avoided. In the 
modern economic environment, the issue of crisis management is increasingly involved in 
business life and leadership. Some industries are evidently more vulnerable to crises than 
others, as a result of their nature, the complexity of regulations wherein they operate and 
their internal procedures. The pharmaceutical industry is undoubtedly quite vulnerable to 
crises, as its companies play a vital role in improving people’s life, treating patients and fi nd-
ing new medicines for uncured diseases. Thus, the potential socio-economic impact of a cri-
sis situation in such an industry is expected to be signifi cant. Moreover, crises have no geo-
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graphical boundaries and they typically cause international cascading eff ects, depending on 
the type of organization and the operational model of each industry. Despite their inability 
to predict crises, organizations do know that crises will happen and the better they are pre-
pared the sooner will come out of this unfavorable situation.
The present study constitutes an eff ort to enrich the crisis management research in 
Greece, which is particularly limited in the pharmaceutical sector (Priporas and Vangelinos, 
2008) as well as the other types of industrial activity. It additionally suggests a comprehen-
sive framework of crisis management and a best practice model, in the form of a guideline 
for the business leaders in the Greek pharmaceutical market. The proposed model, its fi nd-
ings and the relevant recommendations can support crisis management plans and corre-
sponding organizational changes of the given industry. The original research conducted in 
the course of this study encompasses 35 pharmaceutical companies. By and large, the results 
demonstrate that the Greek pharmaceutical sector possesses a considerable level of adop-
tion in crisis management; however, there is room for improving its crisis preparedness, on 
the basis of the proposed toolkit. Specifi cally, it is shown that each company should be pro-
active and not reactive, through planning and taking a series of certain actions to improve its 
crisis management capacity.
2. Families of crisis management strategies
Although it is considered that there are no boundaries for the range of potential crises, it is 
important to recognize the diff erent groups or “families” of crises in order to be prepared (Pear-
son and Mitroff , 1993). Several typologies of crises have been defi ned and examined during the 
last two decades. Pauchant and Mitroff  (1992) grouped crises according to their shared charac-
teristics, referred to as crisis portfolio or “families”. The families consist of the external informa-
tion attacks, external economic attacks, mega damages, breaks, psychological and occupa-
tional health diseases. Coombs (2007) identifi ed the following types of crises: natural disasters, 
malevolence, technical breakdowns, human breakdowns, challenges, mega damages, organi-
zational misdeeds, and that of the workplace. In addition, crisis management has been exam-
ined as a process of an organization dealing with negative events. Especially, Pauchant and 
Mitroff , (1992) defi ne crisis management as the organizational eff orts related to crisis preven-
tion and crisis response. Crisis management incorporates all strategies that an organization 
implements in order to prepare and respond eff ectively to an unpredictable negative event. It 
seeks to minimize the impact of this event and the time of recovery.
Crisis management components have been clustered into 5 families by Pauchant et al. 
(1991), based on previous studies and knowledge. This is a sum-up toolkit of all strategies 
that deal with crisis management. These strategies can be advantageous for the pharmaceu-
tical companies, through helping them to focus in one place using a “quick guide”, where all 
crisis management components have been incorporated. As it is shown in Table 1, the fi ve 
families consist of (a) strategic eff orts and strategies that companies should apply apart from 
the regular strategies in order to be prepared for an eff ective crisis management, (b) struc-
tural and technical eff orts, (c) evaluation and diagnostic eff orts, (d) communications eff orts, 
and (e) psychological and cultural eff orts.
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Table 1 Families of crisis management strategies.
Strategic Eff orts
1. Drastic changes in corporate philosophy
2. Integration of crisis management (CM) into corporate excellence
3. Integration of CM into the strategic planning process
4. Inclusion of outsiders on board, crisis management unit (CMU), etc.
5. Training and workshops in CM
6. Crises simulations
7. Diversifi cation and portfolio strategies 
Technical and structural eff orts
8. Creation of a CMU
9. Creation of dedicated budget for CM
10. Developing and changing emergency policies and manuals
11. Computerized inventories of plants’ employees, products and capabilities
12. Creation of an emergency room or facility
13. Reduction of hazardous products, services and productions
14. Improved overall design and safety of products and production
15. Technological redundancy, such as computer backup
16. Use of outside expert and services in CM
Evaluation and diagnosis eff orts
17. Legal and fi nancial audit of threats and liabilities
18. Modifi cations in insurance coverage
19. Environmental impact audit and respect of security norms
20. Ranking of most critical activities necessary for daily operation
21. Early warning signals detection, scanning, Issues management
22. Dedicated research on potential hidden dangers
23. Critical follow-up of past crises
Communication eff orts
24. Media training for CM
25. Major eff orts in public relations
26. Increased information to local communities
27. Increased relationships with intervening groups (police, media, etc.)
28. Increased collaboration or lobbying among stakeholders
29. Use of new communication technologies
Psychological and cultural eff orts
30. Strong top management commitment to CM
31. Increased relationships with activist groups
32. Improved acceptance of whistleblowers
33. Increased knowledge of criminal behavior
34. Increased visibility of crises’ human impact on employees
35. Psychological support to employees
36. Stress management and management of anxiety
37. Symbolic reminding of past crises and dangers
Source: Pauchant, et al. (1991).
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According to Fink (1986), it is essential to establish a crisis management team (CMT) 
before developing a preparation plan. The CMT may be composed of diff erent members, 
with distinct roles and responsibilities, depending on the type of crisis. The core team to 
handle a crisis should include, at least, the CEO or the CFO and the crisis communication 
executive, which, in the pharmaceutical industry, is typically the external aff airs executive. 
The CMT members should meet regularly to assess and review the crisis plans. Managing a 
crisis requires cooperation and contribution by numerous individuals aiming in the diversity 
of functions. The CMT should also provide the guidelines for managing a crisis (Coombs, 
2006). It is the “heart” of crisis management, responsible to treat all aspects of a crisis from 
the basics to the end (Stotka and Miller, 2002).
In a nutshell, the existing literature has provided a clear view of the eff orts and strategies 
that an organization should apply to be prepared when a crisis hits. A best practice model 
incorporates eff orts, processes and strategies that will be included in the crisis management 
plan. More specifi cally, crisis management should be part of the culture of each organization 
and should be incorporated in the planning process. The corporate excellence should focus 
on reducing the potential crises by changing the mentality of how organizations operate 
and produce products. Crisis scenarios should be created using external resources and third 
parties, based on previous or future crises. A crisis management team should be established 
including all appropriate people with clear roles, responsibilities, and expected results. Con-
tingency plans including facilities, backups of systems processes and operations should be 
ready in case of a crisis, so as to operate in the most effi  cient and proper way. The organiza-
tions should have pre-arranged conference and backup rooms to provide updates and rele-
vant information to the media. Appointed spokespersons and clear communication plan 
and channels should be established so as to reach people inside and outside with the most 
appropriate way.
3. The research in the Greek pharmaceutical sector
The empirical research about crisis management in Greece is very limited, both for the 
pharmaceutical sector as well as the whole industry. The outbreak of global economic crisis 
in 2008, the fi scal debt crisis in Eurozone, the withdrawal of Greece from international bond 
markets and its inclusion in the three-party (EU, ECB, IMF) fi scal support mechanism in 2010, 
as a result of its high debt and public defi cit, underline the need for deploying eff ective crisis 
management plans. Nevertheless, most companies do not usually examine the possibilities 
of crisis and they are not adequately prepared to handle them. 
Regarding the health sector, the Greek government has already completed the largest 
part of the Economic Adjustment Programme 2011-2014, including the changes in primary 
health care services, the reduction of pharmaceutical expenses and the penetration of gener-
ics. According to SFEE (2013), the per-capita public expenditure for pharmaceutical products 
is declined since 2009, as it was reduced from 456€ to 214€ in 2013, while further reduction 
is expected in 2014 (183€). The business leaders of the pharmaceutical industry should 
actively participate in this adjustment eff ort and be prepared to manage future crises, 
through developing suitable skills, plans and strategies. The proposed model can support 
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this process, by helping pharmaceutical companies to understand and assess sources of risk, 
potential problems and management practices.
As far as the current research characteristics are concerned, credibility with the respond-
ents was established by using an introductory letter, which clearly defi ned the purpose of 
research and potential usage of the responses. Furthermore, it was clarifi ed that confi dential-
ity and anonymity of respondents would be granted. A pre-research communication 
informed the respondents about the questionnaire structure and provided insight about its 
completion, to avoid misunderstanding and save time. The structured questionnaire was 
designed to identify the level of readiness of the pharmaceutical companies in Greece, in 
relation to the 5 families of crisis management. 
The questionnaire involved 7 sections, starting from the demographic section, with ques-
tions based on predefi ned selections to capture the demographic data. The second section 
aimed to capture the crises that each company may have faced, including the perception of 
the level of preparedness, to allow the comparison with the actual eff orts of preparedness, as 
described in the following 5 sections. The rest 5 sections included questions based on the 5 
families of crisis management, in accordance with the research objectives. The questionnaire 
consisted of only closed-ended simple questions, specifi c and adapted to strategies exclu-
sively.
It is also noted that the questionnaire incorporated questions from already established 
surveys developed by Pauchant and Mitroff  (1992), Guimaraes (1997), Dinkin (2007), and the 
Institute of Certifi ed Professional Managers (2010). This approach contributed to the 
enhanced quality and time saving, as there was no need for pilot study. The survey popula-
tion refers to the total number (about 100) of pharmaceutical companies operating in Greece, 
based on SFEE (2013). Based on the number of responses to the questionnaire within the set 
timeframe, the research was limited to 35 companies. Nonetheless, 35% of the total popula-
tion is regarded as an adequately representative and satisfactory sample size for the validity 
and reliability of the research, and the generalization of conclusions.
4. Research results
The analysis of collected data reveals that 71% of the pharmaceutical companies are for-
eign / multinational. The majority of them (57%) has more than 99 employees. Among the 
respondents, 68% are in a managerial level, 6% supervisors, 20% executives and 6% manag-
ing directors. Besides, 60% work for the sales & marketing departments, while 68% are in the 
same pharmaceutical company during, at least, the last 5 years. This is another factor which 
adds to the overall confi dence for high-accuracy responses about the crisis management. 
The educational level of pharmaceutical business leaders is very high, as 71% has MBA and 
14% PhD. Almost 97% of the respondents has experienced at least one crisis in the past 5 
years. This outcome verifi es the hypothesis that the pharmaceutical companies are highly 
vulnerable to crises. Figure 1 presents the proportion and the number of companies which 
faced a crisis situation during the 5 past years.
A deeper analysis regarding the types of crisis faced by pharmaceutical fi rms in Greece 
(Figure 2), it shows that the market crash is the number 1 type of crisis, as it was indicated by 18 
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fi rms. The second most usual type of crisis refers to the regulatory and legislation crisis, which 
was indicated by 16 fi rms. These results can be justifi ed by the fact that Greece experiences a 
severe economic crisis since 2008 and, during all these years, the market is collapsing. Next in 
the order of importance, a crisis situation corresponding to a major decline in stock price, a 
failed drug clinical trial, a loss of key executive/person, and cash fl ow/liquidity problem was 
identifi ed by an equal number of (ten) fi rms. By and large, pharmaceutical business leaders 
believe that they are highly prepared for the top three types of crisis, i.e. cash fl ow, corruption 
and legal issues, and drug recall. Crisis readiness is their fi rst priority topic and they believe that 
pharmaceutical companies should focus on how to manage crisis. They also consider that 
pharmaceutical companies have a high possibility to face an adverse event and that they are in 
the position to face a crisis with use of proactive strategies rather than reactive ones.
More detailed results concerning the questions, answers and scores for the various fami-
lies of crisis management strategies adopted by the Greek pharmaceutical companies are 
presented in Table 2. More specifi cally, regarding the strategic eff orts, the overall score is 
17.38, which is above the medium level (16), but not higher than 20, in order to be classifi ed 
to the high level of preparedness. Hence, taking into account the overall score and based on 
the suggested model, the Greek pharmaceutical sector has medium-level preparedness in 
the strategic eff orts. Regarding the level of preparedness for technical & structural eff orts, 
the analysis of the responses from all eff orts of this family reveals that the overall score is 
30.97, which is above the high level (30), but not higher than 36, in order to be considered as 
very high. Taking into account the overall score and based on the suggested model, the 
Greek pharmaceutical sector has a high level of preparedness in the family of technical and 
structural eff orts. 
As far as the level of preparedness for evaluation and diagnosis eff orts is concerned, the 
analysis of the responses from all eff orts of this family indicates that the overall score for the 
Figure 1 Proportion (%) and number of companies within the sample that faced a crisis situation 
during the 5 past years.
Source: Authors’ work.
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pharmaceutical companies is 20.05, which is above the high level (20). Therefore, taking into 
account the overall score and based on the suggested model, the pharmaceutical sector has 
a high level of preparedness in the family of evaluation and diagnosis eff orts. Regarding the 
level of preparedness for communicational eff orts, the analysis of the responses from all 
eff orts of this family suggests that the overall score is 23.7, which is above the medium level 
(20), but not higher than 25, so as to be considered as high level of preparedness. Taking into 
account the overall score and the suggested model, the pharmaceutical sector has medium- 
level preparedness in the communicational eff orts. 
In relation to the level of preparedness for psychological and cultural eff orts, the analysis 
of the responses from all eff orts of this family suggests that the overall score is 20.69, which 
is marginally above the medium level (20) and for sure not higher than 25, so as to be consid-
Figure 2 Number of crisis types faced by pharmaceutical fi rms in Greece during the 5 past years.
Source: Authors’ work.
14
Laura Maska, Theodore Tsekeris, Christos Kadas, Charalambos Tsekeris
ered as high level of preparedness. Taking into account the overall score and based on sug-
gested model, the pharmaceutical sector has medium-level preparedness in the psychologi-
cal and cultural eff orts. At this stage, it should be highlighted that the score of the pharma-
ceutical sector is marginally on medium level.










Is crisis management (CM) 
integrated into planning 2 3 4 5 6 4.89
Outside Experts 2 3 4 5 6 3.89
Provide trainings, workshops in CM 2 3 4 5 6 4.66
CM simulations 2 3 4 5 6 3.94
Total 8 12 16 20 24 17.38
Technical and 
structural eff orts
CMU Team in Place 2 3 4 5 6 5.00
Budget for crisis management 2 3 4 5 6 3.69
Policies/emergencies manuals 2 3 4 5 6 5.11
Computerized inventories 2 3 4 5 6 4.94
Improving Drug or Production 2 3 4 5 6 5.86
Backup systems for computer 2 3 4 5 6 6.37
Total 12 18 24 30 36 30.97
Evaluation and 
diagnosis eff orts
Internal Audits, Finance 2 3 4 5 6 6.43
Early signs for an upcoming crisis 2 3 4 5 6 5.23
Research for potential crises 2 3 4 5 6 3.74
Rank activities ensure operation 2 3 4 5 6 5.11
Total 8 12 16 20 24 20.5
Communicational 
eff orts
Is a spokesperson appointed 2 3 4 5 6 5.14
Training with the media 2 3 4 5 6 4.57
Health communities relationships 2 3 4 5 6 5.66
Cooperation with them 2 3 4 5 6 4.66
Plan include Twitter, Facebook 2 3 4 5 6 3.69
Total 10 15 20 25 30 23.7
Psychological and 
cultural eff orts
CEO Commitments in CM 2 3 4 5 6 5.43
Top Management communication 2 3 4 5 6 4.83
Relationships with Activists 2 3 4 5 6 2.91
Psychological support services 2 3 4 5 6 3.29
Are people rewarded 2 3 4 5 6 4.23
Total 10 15 20 25 30 20.69
Source: Authors’ work.
Next, a number of 5 steps are created to illustrate and characterize the level of usage of 
the crisis management families, starting from the “Aware” companies, and then to the “Con-
sider” companies, the “Prepared” companies, the “Advanced” companies and the crisis man-
agement “Leader” companies. Each of these steps has specifi c attributes and cutoff s, as pre-
sented in Figure 1. For instance, a company is ranked as “Advanced” in crisis management 
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when it has in place all the strategic eff orts and evaluation/diagnostic eff orts and, at least, 4 
eff orts in the rest of the families. In addition, a simplifi ed best-practice model, referred to as 
Crisis Management Adoption Ladder, is designed to evaluate and rank the fi rms’ eff orts when 
dealing with crisis, based on the clusters of readiness. Subsequently, risk levels are created so 
as to alert the companies and not just inform them about the crisis management adoption 
level (Figure 3). Companies who are placed in Level 1 and 2 are in high risk and are considered 
as crisis-prone organizations. Pharmaceutical companies ranked at Level 3 are regarded as 
prepared and to be stable from a risk perspective. However, this ranking does not imply that 
they do not face any risk. Organizations which belong to Level 4 and Level 5 are considered 
as secured and crisis-advanced organizations.
In general, pharmaceutical organizations in Greece use a signifi cant number of strategies 
from the 5 families. They mainly focus on technical and structural eff orts, as these strategies 
Figure 3 Classifi cation of pharmaceutical fi rms in Greece according to their crisis preparedness level.
Source: Authors’ work.
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are the simplest to implement and most common across the industries. Pharmaceutical 
companies also deploy a signifi cant number of evaluation and diagnostic eff orts (Table 2). On 
the other hand, there are strategies from the rest of the families, such as that of psychological 
and cultural eff orts, which clearly require additional sources to enhance their implementa-
tion. More specifi cally, the analysis and clustering of fi rms reveal that 77.1% of them are per-
ceived as crisis-prepared with a stable risk factor, one company (2.9%) is the leader in crisis 
management adoption, as it applies almost all eff orts and strategies from all families of crisis 
management, 5.7% are in the advanced level of crisis management adoption, and 14.3% are 
in the “Consider” level of crisis management adoption, facing a severe risk in a future crisis.
5. Conclusion 
The objective of the present study is twofold. First, it performs the measurement of the 
crisis preparedness level of pharmaceutical companies operating in Greece, based on the 5 
families of crisis management, as described by Pauchant et al. (1991). It should be noted here 
that, although the specifi c method provides a satisfactory approach for classifying compa-
nies according to their crisis readiness, some updates that incorporate recent (technological 
and organizational) advances in handling crisis at the fi rm level would promote the proposed 
model. Second, it creates a simplifi ed toolkit for immediate use, based on the crisis manage-
ment model, to provide all pharmaceuticals companies with comprehensive scoring and a 
clear guidance for the level of risk they probably have, depending on their step in the crisis 
management adoption ladder.
The processing of the original survey data from 35 pharmaceuticals companies demon-
strate that the business leaders of this industry are highly educated with long experience 
and they operate proactively, being confi dent that they will face a crisis. This outcome refl ects 
the relatively high level of crisis readiness of pharmaceuticals companies in evaluation/diag-
nostic eff orts as well as in technical/structural eff orts of crisis management. The essential 
contribution of these two strategies to the overall crisis management in the given sector can 
be attributed to the fact that those families are the easiest to implement initially. The medium 
level of preparedness in relation to the families of strategic eff orts, communication eff orts 
and psychological/cultural eff orts highlights the importance of taking actions in these crisis 
management fi elds.
The study reveals that a high percentage (≈86%) of pharmaceuticals organizations oper-
ating in Greece is in the “Prepared” or a higher level of the crisis management adoption lad-
der. The latter outcome does not mean that pharmaceutical companies are not at risk, but it 
depicts the actual eff ort of this industry to survive in a volatile economic environment and 
operate smoothly. The sectoral average level of risk is moderate, while 14% of companies are 
found at a high risk and, hence, they should take immediate actions to become crisis-pre-
pared organizations. The present modeling/evaluation framework is applicable and poten-
tially useful for managing crisis in several other industries of the Greek economy.
17
MEASURING THE CRISIS PREPAREDNESS 
IN THE PHARMACEUTICAL SECTOR: THE CASE OF GREECE
B I B L I O G R A P H Y
1. Colin D., (2005), Crisis Management in the Food and Drinks Industry: A Practical Approach, 
New York: Springer.
2. Coombs, W. (2006), Code red in the boardroom: Crisis management as organizational DNA, 
Westport, CT: Praeger.
3. Coombs, W.T. (2007), Ongoing crisis communication: Planning, managing, and responding, 
2nd ed. Thousand Oaks, CA: Sage.
4. Dinkin, D.R. (2007), Organizational Crises in Local North Carolina Public Health Agencies: A 
Crisis Typology & Assessment of Organizational Preparedness, Chapel Hill, NC.
5. Fink, S. (1986), Crisis Management: Planning for the Inevitable, New York: American 
Management Association.
6. Institute of Certifi ed Professional Managers (2010), Crisis Communications Management 
Readiness Questionnaire, James Madison University, MSC 5504, Harrisonburg, VA.
7. Pauchant, T., Mitroff , I., and Lagadec, P. (1991), “Toward a systemic crisis management 
strategy. Learning from the best examples in the US, Canada and France”, Industrial Crisis 
Quarterly, 5 (3), pp. 209-232.
8. Pauchant, T.C., and Mitroff , I.I. (1992), Transforming the Crisis Prone Organization, San Fran-
cisco, CA: Jossey-Bass, Inc.
9. Pearson, C.M. and Mitroff , I.I. (1993), “From Crisis Prone to Crisis Prepared: A Framework 
for Crisis Management”, Academy of Management Executive, Vol. 7, No. 1, pp. 48-59.
10. Priporas, C.V., and Vangelinos, G. (2008), “Crisis management in pharmaceuticals: evi-
dence from Greece”, International Journal of Pharmaceutical and Healthcare Marketing, 
Vol. 2, No. 2, pp. 88-102.
11. SFEE (2013), The Pharmaceutical Market in Greece: Facts and Data, Athens: Hellenic Asso-
ciation of Pharmaceutical Companies.
12. Stotka, J.L., and Miller, M.A. (2002), “Managing a crisis eff ectively: A blue print for pharma-
ceuticals companies”, Drug Information Journal, Vol. 36, 325-331.
18
Laura Maska, Theodore Tsekeris, Christos Kadas, Charalambos Tsekeris
Sažetak
MJERENJE KRIZNE PRIPRAVNOSTI U FARMACEUTSKOM SEKTORU: SLUČAJ GRČKE
Ovaj rad donosi pregled bitnih komponenti u upravljanju kriznim situacijama i empirijsku analizu 
pripravnosti za upravljanje kriznim situacijama farmaceutskih tvrtki u Grčkoj. Također, rad pred-
stavlja model najbolje prakse za vodeće tvrtke na grčkom farmaceutskom tržištu kako bi im 
pomogao da procijene njihovu razinu pripremljenosti i da kreiraju vlastite planove upravljanja kri-
zama, prilagođavajući trenutne rezultate istraživanja. Rezultati dobiveni iz izvorne ankete odnosno 
upitnika, potvrđuju da je farmaceutska industrija posebno osjetljiva na krizne situacije i da je grčka 
gospodarska kriza imala ozbiljan nepovoljan utjecaj na tu industriju. Ipak, rezultati istraživanja 
ukazuju na to da farmaceutske tvrtke u Grčkoj imaju respektabilnu razinu usvajanja upravljanja 
kriznim situacijama, iako još uvijek postoji prostor za poboljšanja u rješavanju različitih vrsta 
budućih tržišnih rizika.
Ključne riječi: krizna pripravnost, usvajanje upravljanja rizicima, farmaceutski sektor, Grčka.
